Restructuring and Asset Impairment Charges (Tables)

6 Months Ended

Sep. 30, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

Restructuring charges for the preliminary phase of our strategic growth initiative consisted of the following for the second quarter of 2019:

(In millions)	U.S. Pharmaceutical and Specialty Solutions		Medical-Surgical Solutions		Other		Total
Severance and employee-related costs, net	$	—	$	—	$	6	$	6
Exit-related costs (1)	5		5		35		45
Asset impairments and accelerated depreciation	—		1		1		2
Total	$	5	$	6	$	42	$	53

(1)    Exit-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within our Canadian business.

Restructuring charges for the preliminary phase of our strategic growth initiative consisted of the following for the first six months of 2019:

(In millions)	U.S. Pharmaceutical and Specialty Solutions		Medical-Surgical Solutions		Other		Total
Severance and employee-related costs, net	$	3	$	10	$	7	$	20
Exit-related costs (1)	6		7		56		69
Asset impairments and accelerated depreciation	4		1		17		22
Total	$	13	$	18	$	80	$	111

(1)    Exit-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within our Canadian business.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the the preliminary phase of the strategic growth initiative for the first six months of 2019:

(In millions)	U.S. Pharmaceutical and Specialty Solutions			Medical-Surgical Solutions			Other			Total
Balance, March 31, 2018	$	—		$	—		$	—		$	—
Net restructuring charges recognized	13			18			80			111
Non-cash charges	(4		)	(1		)	(17		)	(22		)
Cash payments	(6		)	(7		)	(18		)	(31		)
Balance, September 30, 2018	$	3		$	10		$	45		$	58